TauC3 Biologics
Private Company
Funding information not available
Overview
TauC3 Biologics is a private, preclinical-stage biotech developing novel antibody-based therapies targeting pathological tau in neurodegenerative diseases. The company is assembling a leadership team with deep expertise in neuroscience drug development, finance, and business strategy. Its mission is to address the high unmet medical need in tauopathies like FTD and PSP, which currently lack disease-modifying treatments.
Technology Platform
Precision immunotherapy platform targeting pathological tau, potentially focused on specific fragments like TauC3, to halt cell-to-cell spread and aggregation.
Opportunities
Risk Factors
Competitive Landscape
The tau therapeutic space is competitive, with several companies (e.g., Biogen, AbbVie, AC Immune) in mid-to-late stage clinical trials for Alzheimer's and PSP. TauC3's differentiation may lie in its precise epitope targeting and focus on primary tauopathies for initial proof-of-concept.